Pharmala Biotech Holdings Inc. (CSE:MDMA)

Pharmala Biotech Holdings Revenue

Pharmala Biotech Holdings had revenue of 513.23K CAD in the quarter ending May 31, 2026, with 279.70% growth. This brings the company's total for the last twelve months to 1.27M, up 201.24% year-over-year. In the fiscal year ending August 31, 2025, Pharmala Biotech Holdings had annual revenue of 605.50K, down -41.51%. That makes Pharmala Biotech Holdings the 43,758th largest company in the world by revenue and 915th in Canada.

• Revenue (ttm): 1.27M
• Revenue Growth: +201.24%
• P/S Ratio: 14.71
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 18.65M

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• United States 350.25K 57.8%
• Australia 225.67K 37.3%
• Canada 29.58K 4.9%

Fiscal year ended Aug 31, 2025 See the full Pharmala Biotech Holdings breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Aug 31, 2025	605.50K	-429.80K	-41.51%
Aug 31, 2024	1.04M	503.29K	94.60%
Aug 31, 2023	532.00K	453.93K	581.44%
Aug 31, 2022	78.07K	-	-
Aug 31, 2021	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Jul 29, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 26, 2026

Data Sources Report a data error